On the 3rd morning, Ildong Pharmaceutical shares rose more than 10%. It is seen as the impact of a securities firm's analysis that the stock is excessively undervalued despite globally competitive technology proven in clinical trials.
As of 9:26 a.m. on the day, Ildong Pharmaceutical was trading at 26,400 won on the Korea Exchange, up 2,900 won (12.34%) from the previous trading day.
Researcher Lee Seon-gyeong at SK Securities said, "The small-molecule GLP-1RA obesity treatment owned by Ildong Pharmaceutical demonstrated the best tolerability and efficacy among competing compounds in the same class through clinical data, but it is seriously undervalued due to the market's misunderstanding of the clinical data."
The researcher added, "If the market's misunderstanding is resolved, we believe Ildong Pharmaceutical's market capitalization could be revised up at least twofold to about 1.5 trillion–4 trillion won, based on the scale of technology transfers for similar pipelines or peers," and set a target price of 45,000 won, 91.5% higher than the previous session's closing price (23,500 won).